Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

2articles mentioning institutions

2institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: NCT05592626 ×

NCT05592626

This institution is selected. Its supporting articles are shown below.

NCT055926262

Articles mentioning NCT05592626

2 articles · page 1 of 1

PARP inhibition combined with a T-cell receptor β chain-directed antibody fusion molecule drives polyclonal antitumor immunity and tumor regression

jitc · abstract · 2026-07-01 · 1 matching annotations

79.9%

NCT05592626 olaparib STAR0602 mSTAR1302 Metastatic castration-resistant prostate cancer (mCRPC)mCRPC mSTAR1302-mediated

…monotherapy in anti-programmed death-ligand 1-resistant tumors (NCT05592626). We hypothesized that combining poly ADP-ribose polymerase (PA…

916 A novel anti-TCR Vb targeted bispecific antibody in combination with a poly ADP-ribose polymerase inhibitor (PARPi) enhances anti-tumor immune response in prostate cancer models

jitc · abstract · 2025-11-04 · 1 matching annotations

84.8%

NCT05592626 mCRPC Olaparib STAR0602 prostate cancer mSTAR1302 IL-2 TRAMP-C2

…ate, STAR0602 is being evaluated in a Phase 1/2 clinical trial (NCT05592626) for the treatment of advanced solid tumors and preliminary res…